Literature DB >> 33259803

Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.

Vladimir Roudko1, Cansu Cimen Bozkus1, Theofano Orfanelli2, Christopher B McClain1, Caitlin Carr2, Timothy O'Donnell3, Lauren Chakraborty4, Robert Samstein1, Kuan-Lin Huang3, Stephanie V Blank2, Benjamin Greenbaum5, Nina Bhardwaj6.   

Abstract

Microsatellite instability-high (MSI-H) tumors are characterized by high tumor mutation burden and responsiveness to checkpoint blockade. We identified tumor-specific frameshifts encoding multiple epitopes that originated from indel mutations shared among patients with MSI-H endometrial, colorectal, and stomach cancers. Epitopes derived from these shared frameshifts have high population occurrence rates, wide presence in many tumor subclones, and are predicted to bind to the most frequent MHC alleles in MSI-H patient cohorts. Neoantigens arising from these mutations are distinctly unlike self and viral antigens, signifying novel groups of potentially highly immunogenic tumor antigens. We further confirmed the immunogenicity of frameshift peptides in T cell stimulation experiments using blood mononuclear cells isolated from both healthy donors and MSI-H cancer patients. Our study uncovers the widespread occurrence and strong immunogenicity of tumor-specific antigens derived from shared frameshift mutations in MSI-H cancer and Lynch syndrome patients, suitable for the design of common "off-the-shelf" cancer vaccines.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33259803      PMCID: PMC8025604          DOI: 10.1016/j.cell.2020.11.004

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  69 in total

1.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system.

Authors:  Massimo Andreatta; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-10-29       Impact factor: 6.937

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Authors:  Whijae Roh; Pei-Ling Chen; Alexandre Reuben; Christine N Spencer; Peter A Prieto; John P Miller; Vancheswaran Gopalakrishnan; Feng Wang; Zachary A Cooper; Sangeetha M Reddy; Curtis Gumbs; Latasha Little; Qing Chang; Wei-Shen Chen; Khalida Wani; Mariana Petaccia De Macedo; Eveline Chen; Jacob L Austin-Breneman; Hong Jiang; Jason Roszik; Michael T Tetzlaff; Michael A Davies; Jeffrey E Gershenwald; Hussein Tawbi; Alexander J Lazar; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Sapna P Patel; Scott E Woodman; Rodabe N Amaria; Victor G Prieto; Jianhua Hu; Padmanee Sharma; James P Allison; Lynda Chin; Jianhua Zhang; Jennifer A Wargo; P Andrew Futreal
Journal:  Sci Transl Med       Date:  2017-03-01       Impact factor: 17.956

Review 4.  Genetic prognostic and predictive markers in colorectal cancer.

Authors:  Axel Walther; Elaine Johnstone; Charles Swanton; Rachel Midgley; Ian Tomlinson; David Kerr
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

5.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.

Authors:  Israel Zighelboim; Paul J Goodfellow; Feng Gao; Randall K Gibb; Matthew A Powell; Janet S Rader; David G Mutch
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

Review 6.  Microsatellite Instability as a Biomarker for PD-1 Blockade.

Authors:  Jonathan C Dudley; Ming-Tseh Lin; Dung T Le; James R Eshleman
Journal:  Clin Cancer Res       Date:  2016-02-15       Impact factor: 12.531

7.  Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.

Authors:  Claudia Maletzki; Fabian Schmidt; Wilhelm G Dirks; Michael Schmitt; Michael Linnebacher
Journal:  Eur J Cancer       Date:  2013-04-02       Impact factor: 9.162

Review 8.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

9.  Systematic characterization of pan-cancer mutation clusters.

Authors:  Marija Buljan; Peter Blattmann; Ruedi Aebersold; Michael Boutros
Journal:  Mol Syst Biol       Date:  2018-03-23       Impact factor: 11.429

Review 10.  Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens.

Authors:  Sandra Wagner; Christina S Mullins; Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2018-12-28       Impact factor: 5.742

View more
  35 in total

Review 1.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

2.  Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.

Authors:  Zaki Molvi; Richard J O'Reilly
Journal:  Cancer Treat Res       Date:  2022

3.  A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses.

Authors:  Cansu Cimen Bozkus; Ana Belen Blazquez; Tomohiro Enokida; Nina Bhardwaj
Journal:  STAR Protoc       Date:  2021-08-17

Review 4.  Vaccines for immunoprevention of cancer.

Authors:  Tomohiro Enokida; Alvaro Moreira; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

5.  Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.

Authors:  Frank J Lowery; Sri Krishna; Rami Yossef; Neilesh B Parikh; Praveen D Chatani; Nikolaos Zacharakis; Maria R Parkhurst; Noam Levin; Sivasish Sindiri; Abraham Sachs; Kyle J Hitscherich; Zhiya Yu; Nolan R Vale; Yong-Chen Lu; Zhili Zheng; Li Jia; Jared J Gartner; Victoria K Hill; Amy R Copeland; Shirley K Nah; Robert V Masi; Billel Gasmi; Scott Kivitz; Biman C Paria; Maria Florentin; Sanghyun P Kim; Ken-Ichi Hanada; Yong F Li; Lien T Ngo; Satyajit Ray; Mackenzie L Shindorf; Shoshana T Levi; Ryan Shepherd; Chris Toy; Anup Y Parikh; Todd D Prickett; Michael C Kelly; Rachel Beyer; Stephanie L Goff; James C Yang; Paul F Robbins; Steven A Rosenberg
Journal:  Science       Date:  2022-02-03       Impact factor: 47.728

6.  Diverse immune response of DNA damage repair-deficient tumors.

Authors:  Tao Qing; Tomi Jun; Katherine E Lindblad; Amaia Lujambio; Michal Marczyk; Lajos Pusztai; Kuan-Lin Huang
Journal:  Cell Rep Med       Date:  2021-05-18

7.  Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Authors:  Yoland Antill; Peey-Sei Kok; Kristy Robledo; Sonia Yip; Michelle Cummins; Deborah Smith; Amanda Spurdle; Elizabeth Barnes; Yeh Chen Lee; Michael Friedlander; Sally Baron-Hay; Catherine Shannon; Jermaine Coward; Philip Beale; Geraldine Goss; Tarek Meniawy; Janine Lombard; John Andrews; Martin R Stockler; Linda Mileshkin
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 8.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 9.  Mutational signatures: emerging concepts, caveats and clinical applications.

Authors:  Gene Koh; Andrea Degasperi; Xueqing Zou; Sophie Momen; Serena Nik-Zainal
Journal:  Nat Rev Cancer       Date:  2021-07-27       Impact factor: 60.716

Review 10.  The abscopal effect: a sense of DNA damage is in the air.

Authors:  Timothy P Lippert; Roger A Greenberg
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.